The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients

Diabetes Care

Volumn 19, Issue 11, 1996, Pages 1200-1206

  Juntti Berggren, Lisa ^a,b   Pigon, Jan ^a,b   Karpe, Fredrik ^b   Hamsten, Anders ^b   Gutniak, Mark ^c   Vlgnati, Louis ^c   Efendic, Suad ^a  

^a Unit for Diabetes and Endocrinology   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCOSE; INSULIN; ISOPHANE INSULIN; LIPOPROTEIN LIPASE; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES CONTROL; DYSLIPOPROTEINEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN TREATMENT; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZATION; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0029857454     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.19.11.1200     Document Type: Article

References (40)

1. Kreymann B, Williams G, Ghatei MA, Bloom SR: Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet ii: 1300-1303,1987
2. Fehmann HC, Göke R, Göke B: Glucagonlike peptide-l(7-37)/(7-36)amide is new incretin. Mo! Cell Endocrine! 85:C39-C44, 1992
3. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Eben R, Creutzfeldt W: Preserved incretin activity of glucagon-like peptide-1 (7-36)amide but not of synthetic human gastric inhibitor)' polypeptide in patients with type 2 diabetes mellitus. J Clin Invest 92:301-307,1993
4. Gutniak MK, Orskov C, Holst JJ, Ähren B, Efendic S: Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Eng! J Med 326:1316-1322, 1992
5. Nathan DM, Schreiber E, Mqjsov S, Habener JF: Insulinotropic action of glucagon-like peptide-1 (7-37) in diabetic and nondiabetic subjects. Diabetes Care 15:270-276,1992
6. Nauck MA, Kleine N, Orskov C, Hoist JJ, Willms B, Creutzfeldt \V: Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide-l(7-36)amide in type 2(non-insulin-dependent) diabetic patients. Diabetologia. 36:741-744, 1993
7. Wettergren A, Schjoldager B, Mortensen PE, MyhreJ, ChristiansenJ, Hoist JJ: Truncated GLP-1 (proglucagon 78-107amide) inhibits gastric and pancreatic functions in man. Dig Dis Sei 38:665-673, 1993
8. Willms B, Werner J, Hoist JJ, Orskov C, Creutzfeldt W, Nauck MA: Gastric emptying, glucose responses, and insulin secretion after liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)(7-36)amide in type 2 (noninsulindependent) diabetic patients. J Clin Endocrinol Metab 81:327-332,1996
9. Gutniak MK, Juntti-Berggren L, Hellström PM, Guenifi A, Hoist JJ, Efendic S: Glucagon-like peptide 1 enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas. Diabetes Care 19:857-863,1996
10. Howard BV: Lipoprotein metabolism in diabetes mellitus. ]Upid Res 28:613-628,1987
11. Feingold KR, Grunfeld C, Pang M, Doerr-1er \V Krauss RM: LDL subclass phenotypes and triglycéride metabolism in noninsulin-dependent diabetes. Arteriosder Uromb 12:1496-1502, 1992
12. Detwart MV Laker MI; Dyer RG, Game E. Mitcheson J, Winocour PH, Alben KGMM: Lipoprotein compositional abnormalities and insulin resistance in type II diabetic patients with mild hyperlipidemia. ArteriosderThromb 13:1046-1052,1992
13. Barakat HA, CarpenterJ\Y McLendon VD, Khazanie P, Leggett N, Heath J, Marks R: Influence of obesity, impaired glucose tolerance and NIDDM on LDL structure and composition. Diabetes 39:1527-1533, 1990
14. Laakso M, Lehto S, Penttilâ I, Pyôrâlâ K: Lipids and lipoproteins predicting coronary hean mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation 88:1421-1430, 1993
15. Uusitupa MIJ, Niskanen LK, Siitonen O, Vontilainen E, Pyôrâlâ K: Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia 36:1175-1184,1993
16. Fontbonne A, Eschwege E, (Zambien E, Richard JL, Ducimetiere P, Thibult N, Warnet JM, Claude JR, Rosselin GE: Hypertriglyceridemia as a risk factor for coronary hean disease mortality in subjects with impaired glucose tolerance or diabetes: results from an 11 year follow-up of the Paris Prospective Study. Diabetologia 32:300-304,1989
17. Austin MA, Mykkänen L, Kuusisto J, Edwards KL, Nelson C, Haffner SM, Pyôrâlâ K, Laakso M: Prospective study of small LDLs as a risk factor for non-insulin dependent diabetes mellitus in elderly men and women. Gradation 92:1770-1778,1995
18. Knapper JM, Puddicombe SM, Morgan LM, Fletcher JM, Marks V: Glucose dependent insulinotropic polypeptide and glucagon-like peptide-1 (7-36)amide: effects on lipoprotein lipase activity. BiochemSoc Trans 21-.135S, 1993
19. Hugget ASG, Nixon DA: Use of glucose oxidase, peroxidase and o-dianisidine in determination of blood and urinary glucose. Lancet ii:368-370, 1957
20. Simon M, Cuan J: Hemoglobin Alc by isoelectric focusing. Clin Chem 28:9-12, 1982
21. Gennaro WD, Van Norman JD: Quantification of free, total and antibody-bound insulin in insulin-treated diabetics. Clin Chem 21:873-879, 1975
22. Carlson K: Lipoprotein fractionation. J Clin Pathol 5:32-37,1973
23. Zlatkis A, Zak B, Boyle A: New method for direct determination of serum cholesterol. J Lab ClinMed 41:486-492, 1953
24. Fletcher MJ: A colorimetric method for estimating serum triglycérides. Clin Chtm Acta 22:393-397,1968
25. Carlson LA: Determination of serum triglycérides. J Atherosclerosis Res 3:334-336,1963
26. Bengtsson-Olivecrona G, Olivecrona T: Assay of Hpoprotein lipase and hepatic lipase. In Upoprotein Analysis, A Practical Approach. Converse CA, Skinner ER, Eds. Oxford, Oxford University Press, 1992
27. Redgrave TG, Carlson LA: Changes in plasma very low density and low density content, composition and size after a fatty meal in normo-and hypertriglyceridemic man. JLipid Res 20:217-229,1979
28. Nichos AW, Krauss RM, Musliner TA: Nondenaturing polyacrylamide gradient gel electrophoresis. Me(h Enz 128:417-431,1986
29. Rodbard D, Chrambach A: Estimation of molecular radius, free mobility, and valence using polyacrylamide gel electrophoresis. Anal Biochem 40:95-135,1971
30. Gutniak MK, Linde B, Holst JJ, Efendic S: Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abol-ishes postprandial glycemia in N1DDM. Diabetes Care 17:1039-1044,1994
31. Ritzel R, Orskov C, Hokt JJ, Nauck MA: Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLPl(7-36amide) after subcutaneous injection in healthy volunteers: dose-response-relationships. Diabetologia 38:720-725,1995
32. Sherwin RS, Tamborlane W, Hendler R, Saccâ L, DeFronzo RA, Feiig P: Influences of glucagon replacement on the hyperglycémie and hyperketonemic response to prolonged somatostatin infusion in normal man.J Clin Endocrinol Metdb 45:1104-1107,1977
33. Hargrove D, Nardone N, Perrson L, Parker J: Effects of chronic and acute administration of GL1P on glucose stimulated insulin secretion in vivo (Abstract). Diabetes 43 (Suppl. 1):161A, 1994
34. Broderick CL, Heisserman JA, Smiley DL, Miller AR: Effect of sub-chronic administration of GL1P(7-37)OH on beta cell failure in Zucker Diabetic rats (Abstract). Diabetologia 38 (Suppl. 1): A171,1995
35. Fehmann HC, Habener JF: Homologous desensitization of the insulinotropic glucagon-like peptide-l(7-37) receptor on insulinoma (HIT-T15) cells. Endocrinology 128:2880-2888,1991
36. Lindström T, Eriksson P, Olsson AG, Amqvist HJ: Long-term improvement of glycémie control by insulin treatment in NIDDM patients with secondary failure. Diabetes Care 17:719-721,1994
37. Lewis GF, Uffelman KD, Szeto L\Y Weller B, Steiner G: Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans.] Clin Invest 95:158-166,1995
38. Ruotolo G, Parlavecchia M, Taskinen MR, Galimberti G, Zoppo A, Le NA, Ragogna F, Micossi P, Pozza G: Normalization of lipoprotein composition by intraperitoneal insulin in 1DDM: role of increased hepatic lipase activity Diabetes Care 17:6-12,1994
39. Krauss RM: Heterogeneity of plasma lowdensity lipoproteins and atherosclerosis risk. Curr Opin Upidol 5:339-349,1994
40. Austin MA, Hokanson JE, Brunzell JD: Characterization of low-density lipoprotein subclasses: methodological approaches and clinical relevance. Curr Opin Upidol 5:395-403,1994